Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill aims to stop Narcolepsy's sudden muscle weakness

NCT ID NCT05059223

Symptom relief Sponsor: Axsome Therapeutics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an experimental drug called AXS-12 (reboxetine) in 90 people with narcolepsy who experience cataplexy (sudden muscle weakness) and excessive daytime sleepiness. Participants took either the drug or a placebo twice daily for several weeks. The main goal was to see if AXS-12 could reduce the number of cataplexy attacks per week.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AXS-12 (reboxetine)
What this could lead to
If it works, this could provide a new treatment option to reduce sudden muscle weakness and improve daytime alertness in people with narcolepsy.
What could go wrong
This is a Phase 3 trial, but results are not yet published. The drug may not prove more effective than placebo, and side effects like insomnia or increased blood pressure are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

90 people

The number who actually took part.

Started

Sep 2021

Finished

Mar 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

15 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female subjects between 15 and 75 years of age, inclusive * Primary diagnosis of narcolepsy with cataplexy * Willing and able to comply with the study requirements Exclusion Criteria: * Other clinically significant conditions potentially causing EDS * Clinically significant psychiatric disorders

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cataplexy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cataplexy Disorders of Excessive Somnolence hypersomnia narcolepsy narcolepsy 1 narcolepsy-cataplexy syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cataplexy Excessive daytime sleepiness Narcolepsy

Contacts and locations

Locations

  • Clinical Research Site

    Alabaster, Alabama, 35007, United States

  • Clinical Research Site

    Peoria, Arizona, 85381, United States

  • Clinical Research Site

    Phoenix, Arizona, 85054, United States

  • Clinical Research Site

    Redwood City, California, 94063, United States

  • Clinical Research Site

    San Diego, California, 92103, United States

  • Clinical Research Site

    Santa Ana, California, 92705, United States

  • Clinical Research Site

    Santa Monica, California, 90404, United States

  • Clinical Research Site

    Boulder, Colorado, 80301, United States

  • Clinical Research Site

    Colorado Springs, Colorado, 80918, United States

  • Clinical Research Site

    Brandon, Florida, 33511, United States

  • Clinical Research Site

    Clearwater, Florida, 33765, United States

  • Clinical Research Site

    Doral, Florida, 33122, United States

  • Clinical Research Site

    Kissimmee, Florida, 34741, United States

  • Clinical Research Site

    Miami, Florida, 33176, United States

  • Clinical Research Site

    Miami Lakes, Florida, 33016, United States

  • Clinical Research Site

    St. Petersburg, Florida, 33707, United States

  • Clinical Research Site

    Tampa, Florida, 33634, United States

  • Clinical Research Site

    Winter Park, Florida, 32789, United States

  • Clinical Research Site

    Atlanta, Georgia, 30315, United States

  • Clinical Research Site

    Atlanta, Georgia, 30328, United States

  • Clinical Research Site

    Gainesville, Georgia, 30501, United States

  • Clinical Research Site

    Macon, Georgia, 31210, United States

  • Clinical Research Site

    Stockbridge, Georgia, 30281, United States

  • Clinical Research Site

    Honolulu, Hawaii, 96817, United States

  • Clinical Research Site

    Peoria, Illinois, 61637, United States

  • Clinical Research Site

    Fort Wayne, Indiana, 46804, United States

  • Clinical Research Site

    Chevy Chase, Maryland, 20815, United States

  • Clinical Research Site

    Newton, Massachusetts, 02459, United States

  • Clinical Research Site

    North Dartmouth, Massachusetts, 02747, United States

  • Clinical Research Site

    Kalamazoo, Michigan, 49008, United States

  • Clinical Research Site

    Novi, Michigan, 48377, United States

  • Clinical Research Site

    St Louis, Missouri, 63123, United States

  • Clinical Research Site

    Las Vegas, Nevada, 89106, United States

  • Clinical Research Site

    Neptune City, New Jersey, 07753, United States

  • Clinical Research Site

    Brooklyn, New York, 11230, United States

  • Clinical Research Site

    New Hyde Park, New York, 11040, United States

  • Clinical Research Site

    Denver, North Carolina, 28037, United States

  • Clinical Research Site

    Gastonia, North Carolina, 28054, United States

  • Clinical Research Site

    Huntersville, North Carolina, 28078, United States

  • Clinical Research Site

    Cincinnati, Ohio, 45245, United States

  • Clinical Research Site

    Wyomissing, Pennsylvania, 19610, United States

  • Clinical Research Site

    Charleston, South Carolina, 29425, United States

  • Clinical Research Site

    Columbia, South Carolina, 29201, United States

  • Clinical Research Site

    Austin, Texas, 78731, United States

  • Clinical Research Site

    San Antonio, Texas, 78229, United States

  • Clinical Research Site

    Sugar Land, Texas, 77478, United States

  • Clinical Research Site

    Williamsburg, Virginia, 23188, United States

  • Clinical Research Site

    Markham, Ontario, L3R 1A3, Canada

  • Clinical Research Site

    Toronto, Ontario, M4P 1P2, Canada

  • Clinical Research Site

    Toronto, Ontario, M5S 3A3, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.